Veritas Innovation

June research highlights! Check out these three developments that caught our attention at Veritas Innovation:   1.       Advanced Cancer Treatment: Aarhus University researchers combine 4-OI with VSVD51 to enhance treatment for resistant cancers, potentially offering new hope where traditional therapies fall short. (https://lnkd.in/g-ARU6QP) 2.       Portable Diagnostics: University of Pittsburgh's new lab-on-a-chip device uses blood for quick metabolic disorder diagnostics, bridging gaps in healthcare accessibility, especially in remote areas. (https://lnkd.in/g6Grny3j) 3.       Early Parkinson's Detection: UCL and University Medical Center Goettingen use AI to predict Parkinson's up to seven years before symptoms, opening doors to early intervention and disease prevention strategies. (https://lnkd.in/gG_utgNF)   Which breakthrough excites you the most? Let us know if there are any other developments that you found interesting! Explore how Veritas Innovation supports groundbreaking research: https://lnkd.in/gWsJZHKB

May Research Insights: Exploring recent breakthroughs in medical research, three studies have unveiled promising strategies for combating diseases and enhancing therapeutic interventions.   Influenza B Treatment Breakthrough: Vanderbilt University Medical Center researchers have isolated potent human antibodies against influenza B, paving the way for a novel targeted approach to combat this significant public health threat. The antibody FluB-400, showing broad efficacy and potential for intranasal administration, holds promise for both preventing and treating influenza B infections. https://lnkd.in/dSgbvQSK   Precision Cancer Therapy: At Karolinska Institutet, scientists have developed a targeted cancer treatment utilizing small membrane bubbles loaded with drugs and armed with antibodies against tumors. This innovative therapy demonstrates notable reductions in tumor growth and improved survival rates in preclinical models of breast cancer and melanoma. https://lnkd.in/gP3uAc3Y   Protein Delivery Breakthrough: Cornell University researchers have devised a revolutionary method to cloak proteins, enhancing their delivery into cells for therapeutic purposes. By cloaking the proteins with a negatively charged ion, they made them resemble nucleic acids, enabling them to join with positively charged lipids in the nanoparticles. By binding proteins to lipid nanoparticles and mimicking nucleic acids, this technique offers a promising avenue for more effective and safer delivery of protein-based therapeutics in biological research and therapy. https://lnkd.in/g59DdEc9   What are your thoughts on these cutting-edge advancements in medical research? Share your insights below!

April Research Insights: This month's scientific advancements offer remarkable progress in treating some of the most challenging medical conditions. From revolutionary cancer treatments and groundbreaking diabetes research to innovative dietary strategies that boost cancer immunity, the strides we're witnessing could transform future healthcare. Breakthrough in Brain Tumor Treatment: Purdue University's new therapy targets glioblastoma, one of the deadliest brain tumors, using genetically engineered natural killer cells. This innovative immunotherapy, derived from induced pluripotent stem cells, shows potential in preclinical studies for effectively eliminating tumors, offering hope for a more effective treatment. https://lnkd.in/d35xRkwe Advancing Type 1 Diabetes Research: University of Exeter scientists have made strides in understanding type 1 diabetes through a rare genetic mutation in two siblings. This mutation affects the PD-L1 gene, which plays a crucial role in regulating the immune system and preventing autoimmune attacks on pancreatic cells. This discovery not only advances the search for new diabetes treatments but also informs cancer immunotherapy research. https://lnkd.in/dy4C2ENB Vitamin D Enhances Cancer Immunity: Research by the Francis Crick Institute and partners reveals that vitamin D boosts a type of gut bacteria in mice, enhancing cancer immunity. The study found that mice on a vitamin D-rich diet had better responses to immunotherapy and resisted tumor growth more effectively. These findings suggest potential new avenues for cancer treatment involving dietary interventions. https://lnkd.in/gMWsZviv How do these discoveries influence your perspective on future research and healthcare innovations? Share your thoughts! #HealthcareInnovation #BiotechAdvances #ResearchHighlights 

Overview of the FDA's New Rule on Laboratory Developed Tests (LDTs) Here’s what the new regulations imply: Pros: Improved Patient Safety: Aligning LDTs with the regulatory standards of other medical devices enhances their reliability and safety. Increased Credibility: FDA oversight is expected to boost trust and usage among healthcare providers. Standardization: Encourages consistent test quality, which aids in result validation. Cons: Higher Costs: Compliance may be costly, especially for smaller laboratories. Innovation Slowdown: The regulatory process could delay the rollout of new tests. Operational Strain: Laboratories are required to meet new standards, which may stretch resources. Industry Impact: The rule aims to ensure safer and more reliable tests but might impede innovation and operational flexibility. It is crucial for industry professionals to adapt strategically. What are your thoughts on the implications of this new rule on the healthcare industry? Share in the comments! #HealthcareInnovation #FDARegulations #PatientCare https://lnkd.in/gBAjRUia

Why are drugs so much more expensive to develop today? 📈 Clinical Trials and Manufacturing Costs: The bulk of pharmaceutical R&D spending goes towards clinical trials and associated manufacturing costs. Costs per patient ranging from $100,000 to as much as $500,000 for trials involving expensive standard-of-care medicines or hard-to-find patients, such as those with rare diseases. Fragmentation of R&D Activity: The trend towards greater fragmentation of R&D activity and investment, with large pharmaceutical companies relying more on acquiring drugs and technologies from smaller biotechs, has led to potential underinvestment in speculative, capital-intensive applied research. Analytical Assays for Gene or Cell Therapies: For complex cell and gene therapies, developers are required to run numerous analytical assays to assess quality and release a batch, even during early clinical trials. Check out Alex Telford's blog! Alex is the founder of Convoke, a software company helping to increase capital efficiency for drug developers from development to commercialization. #assaydevelopment #drugdiscovery #clinicaltrials

March Research Highlights: From groundbreaking gene editing to novel diagnostic methods, the advancements this month are both inspiring and promising for the future. Here are some highlights that caught our attention: Gene Editing Milestone: Scientists achieved a groundbreaking feat with the development of a genetically altered cow producing human insulin. This innovation holds immense potential for improving insulin production and addressing diabetes management. Read more https://lnkd.in/gXY5etaC Saliva Testing Innovation: Pooled saliva testing emerges as a game-changer in newborn screening, offering accurate detection of cytomegalovirus (CMV). This non-invasive approach could revolutionize early disease detection and intervention for infants. Discover more https://lnkd.in/gjVABxrv Novel Research Insights: Scientists unveil fascinating findings suggesting a link between air pollution exposure and adolescent psychosis risk. This research underscores the importance of environmental factors in mental health outcomes. Explore further https://lnkd.in/d9QhhJMj How do you think these advancements will impact future research and healthcare? Join the discussion! #HealthcareInnovation #MedicalResearch #Breakthroughs #VeritasInnovation

Comparison of four clinically validated testosterone LC-MS/MS assays: This study aimed to compare the performance of four different clinically validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods for testosterone determination by conducting interlaboratory comparisons using human serum samples. The double charcoal-stripped human serum (MSG4000) was employed as a matrix for calibration and quality control in these assays. The study aimed to assess how well different LC-MS/MS methods correlate and harmonize in testosterone quantification, which is important for ensuring accurate and reliable clinical testing across different laboratories.

Research Background: Metabolic syndrome is characterized by a cluster of conditions, including insulin resistance, obesity, hypertension, and dyslipidemia, which increase the risk for cardiovascular diseases and Type II Diabetes Mellitus. As obesity and metabolic syndromes prevail as significant health issues worldwide, there's a growing demand for innovative therapeutic agents. A particular focus has been placed on non-intoxicating constituents of Cannabis sativa, such as cannabidiol (CBD) and its synthetic analogs. H4CBD is a synthetic analogue with similar therapeutic effects to CBD, without the psychoactive properties associated with cannabis use.   Study Objective: The primary aim of the study was to evaluate the efficacy of H4CBD on glucose intolerance and insulin resistance in OLETF rats, an established animal model for human metabolic syndrome. Matrix Used: An interesting aspect of the methodology was the utilization of Mass Spec Gold human serum (MSG3200, from Golden West Diagnostics), which was used to dilute the samples for the High-performance Liquid Chromatography and Mass Spectrometry/Mass Spectrometry (HPLC MS/MS) analyses. The MSG3200 product played a critical role in establishing the bioavailability of H4CBD in the plasma of treated rats.

This study explores the potential link between endogenous estrogens and systolic blood pressure (SBP) in middle-aged and older adults. The study focuses on serum concentrations of 17β-estradiol (E2) and its metabolites, particularly 16α-hydroxyestrone (16α-OHE1) and 16-ketoestradiol (ketoE2), to investigate their associations with SBP. The research, conducted through a cross-sectional study design, analyzed data from a population-based sample of 98 adults aged 55 to 69 in Cook County, Illinois. Serum samples were examined for E2 and 14 estrogen metabolites using mass spectrometry. SBP was measured, and demographic and health history information was collected through questionnaires. Check out our blog for a paper summary and the importance of charcoal stripped serum in the preparation of calibration standards and quality control: https://lnkd.in/gHTQgm4W Full PDF of the original study below:

The research paper titled: A Sensitive and Cost-Effective LC–MS-MS Method for Determination of 1α,25-Dihydroxyvitamin D3 in Human Plasma by Bruce A. Stanley, Jenny P. Dai, Allan Xu, Eric J. Battaglioli, and Robin T. Wilson, published in 2015. The research paper discusses the development of a sensitive and cost-effective method for quantifying 1α,25-dihydroxyvitamin D3 (1,25(OH)2D3) in human plasma. Accurate quantification of 1,25(OH)2D3 is challenging due to its extremely low concentrations in human plasma, typically in the low picograms-per-milliliter range. MSG1000 was utilized to create calibration standards for the analysis. The study presents presents a novel LC–MS-MS method that combines immunoaffinity extraction (IAE), 4-phenyl-1,2,4-triazole-3,5-dione (PTAD) derivatization, and methylamine adduction. This method aims to improve the accuracy, effectiveness, and sensitivity of 1,25(OH)2D3 quantification.